Utilisation of co-testing (human papillomavirus DNAtesting and cervical cytology) after treatment of CIN: a survey of GPs' awareness and knowledgeAustralian Family Physician (2015)
Patients have an increased risk of
persistent/recurrent cervical disease if
they received treatment for a high-grade
squamous intraepithelial lesion (HSIL).
Consequently, understanding whether
co-testing (human papillomavirus [HPV]
DNA testing and cervical cytology) is fully
utilised by general practitioners (GPs) is
After consultation with key stakeholders,
an anonymous, self-completion
questionnaire was developed and
disseminated to GPs who had provided
Responses were received from 745 GPs
(30.9% response rate). A significant
number (34.3%) of GPs were unaware of
the use of co-testing (HPV DNA testing
and cervical cytology) for the management
of patients after HSIL treatment.
Additionally, the majority of GPs reported
they did not ‘always’ receive a clear followup
plan for patients after treatment of an HSIL.
GPs require further support and education
to ensure successful adoption of co-testing
(HPV DNA testing and cervical cytology),
specifically, for patients treated for an HSIL.
Citation InformationMunro, A., Codde, J.P., Semmens, J., Leung, L., Spilsbury, K., Williams, V., Steel, N., Cohen, P., Pavicic, H., Westoby, V., and O'Leary, P. (2015). Utilisation of co-testing (human papillomavirus DNA testing and cervical cytology) after treatment of CIN: a survey of GPs' awareness and knowledge. Australian Family Physician, 44(1-2), 64-68.